ESAB vs GPGI: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: GPGI is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ESAB and GPGI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ESAB and GPGI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

ESAB Corporation, founded in 1904 and spun out as a standalone public company in 2022, is one of the three largest welding and cutting businesses in the world alongside Lincoln Electric and Illinois Tool Works. It sells welding and cutting equipment, automation systems, and the electrodes, wires, and cutting consumables used across general industry, construction, infrastructure, transportation, energy, renewables, and medical gas control. The consumables side generates recurring, razor-and-blades style revenue, and roughly 80% of sales come from outside the United States, with about half of revenue from high-growth regions like South America, India, and Asia Pacific.

Full ESAB guide

GPGI, Inc. is a diversified holding company that trades on the NYSE under the ticker GPGI. It was formerly CompoSecure, the number-one maker of premium metal payment cards (it shipped over 30 million cards in 2025), and it rebranded to GPGI (short for Great Positions in Good Industries) in January 2026 after acquiring Husky Technologies, a global supplier of injection-molding systems and related plastics processing equipment, in a roughly $5 billion deal. The company now reports through two segments, CompoSecure and Husky, each with its own management team, and describes itself as a multi-industry platform designed to acquire and operate market-leading businesses.

Full GPGI guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ESAB drivers: Recurring consumables base; Bolt-on M&A compounding.
• GPGI drivers: CompoSecure card franchise; Husky integration and margin recovery.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Roughly 80% of sales come from outside the U.S., so currency swings and emerging-market demand volatility are the most pressing near-term risks and can overwhelm organic trends in any given quarter. For GPGI, gPGI carries meaningful integration and financial risk after a roughly $5 billion acquisition, including a substantial debt load that makes deleveraging a stated first priority.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ESAB if you believe its drivers more; GPGI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ESAB and GPGI guides.

ESAB. ESAB reported record Q1 2026 sales of about $746 million, up 10% on a reported basis but down roughly 1% on a core-organic basis, with core adjusted EPS of about $1.31. Management guided full-year 2026 sales to roughly $2.85 to $2.95 billion (about 6% to 9% total growth, 2% to 4% organic). With a market cap near $7.5 billion the stock carries a mid-to-high-20s earnings multiple typical of a quality industrial compounder.

GPGI. GPGI now runs at a much larger combined revenue base than the old CompoSecure, roughly $1.6 billion annualized once Husky is included, but its first post-Husky quarter produced a large GAAP net loss driven by a $154 million equity-method investment loss rather than operating collapse. Because reported earnings are distorted by acquisition accounting and a heavy debt load, some analysts lean on measures like price-to-book and adjusted EBITDA instead of standard P/E. Consensus price targets in mid-2026 clustered in the low-to-mid $20s with a broadly constructive tone, though estimates vary widely given the recency of the combination.

Headline figures (approximate, JULY 2026): ESAB shows revenue (ttm) ~$2.85B, q1 2026 sales ~$746M (+10% reported), core adj. ebitda margin ~19%, 2026 sales guidance ~$2.85B to $2.95B; GPGI shows market cap ~$4.9B, q1 2026 consolidated net sales ~$408M, q1 2026 pro forma adjusted net sales ~$421M, q1 2026 adjusted ebitda ~$89M.

ESAB and GPGI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ESAB and GPGI exposure against your real portfolio. It is not an investment adviser.